CONTACT KTMC

Investor Class Action Filed Against OPKO Health, Inc. for Securities Fraud Violations

Notice is hereby given that a class action lawsuit has been filed on behalf of those who purchased or otherwise acquired OPKO Health, Inc. (“OPKO”) (Nasdaq: OPK) securities from September 26, 2013 through September 7, 2018, both dates inclusive (the “Class Period”).

OPKO investors may receive additional information about the case by clicking the link "Submit Your Information" above.

According to the complaint, OPKO is a healthcare company that engages in the diagnostics and pharmaceuticals business in the United States and internationally, including in Ireland, Chile, Spain, Israel, and Mexico.

The Class Period commences on September 26, 2013, when the article "Opko and Its Billionaire CEO Invested in Biozone" appeared on Seeking Alpha. The complaint alleges that the article, as part of a scheme to inflate the price of Biozone Pharmaceuticals ("Biozone"), touted Biozone by using OPKO and OPKO's Chief Executive Officer and Chairman Phillip Frost's ("Frost") ownership in Biozone, as Frost had a reputation as a successful biotech investor.

The complaint alleges that on September 7, 2018, the SEC issued a press release entitled "SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes," which included Frost and OPKO as defendants. The press release stated, in relevant part, "[a]according to the SEC's complaint, from 2013 to 2018, a group of prolific South Florida-based microcap fraudsters . . . manipulated the share price of the stock of three companies in classic pump-and-dump schemes. Miami biotech billionaire Phillip Frost allegedly participated in two of these three schemes.” Following this news, shares of OPKO fell $1.01 or over 18%, before NASDAQ halted the trading of OPKO on September 7, 2018 at 2:34 p.m. EDT at $4.58.

The complaint alleges that throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that:  (1) Defendant Frost and OPKO were engaged in a pump-and-dump scheme with several other individuals and companies in their investments in several penny stocks; (2) this illicit scheme would result in governmental scrutiny including from the SEC; and (3) as a result, the defendants' statements about OPKO's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis as all relevant times.

If you are a member of the class described above, you may no later than November 13, 2018 move the Court to serve as lead plaintiff of the class, if you so choose.

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of their choice, or may choose to do nothing and remain an inactive class member.

Kessler Topaz Meltzer & Check, LLP has not filed a complaint in this matter.  If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
1-888-299-7706 (toll free) or 1-610-667-7706
Or by e-mail at info@ktmc.com

Please complete this form relating to your transactions for OPKO Health, Inc. (Nasdaq:  OPK) securities from September 26, 2013 through September 7, 2018, both dates inclusive (the "Class Period").

Once completed, please click the orange “Submit Your Information” button at the bottom of this page. You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 888.299.7706, or you may submit your information via email at info@ktmc.com.

* Denotes required field
 
 
 
 
 
 
# of Shares
Price per Share
 
 
 
Principal Amount
Amount Paid
Series or CUSIP
 
 
 
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of OPKO Health, Inc. prior to the Class Period?
Are you a current or former employee of OPKO Health, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
disclaimer
I would like to receive
new case alerts by email